OverviewSuggest Edit

Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its product Grafix is a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns. In addition, the Company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.

TypePublic
Founded1992
HQColumbia, US
Websiteosiris.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2018)342(+2%)
Revenue (FY, 2018)$142.8 M
Share Price (Apr 2019)$19

Key People/Management at Osiris Therapeutics

Linda Chang

Linda Chang

CFO
Jason Keefer

Jason Keefer

Interim President & CEO, VP of Marketing
Show more

Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Dr
Show all (1)

Osiris Therapeutics Financials and Metrics

Osiris Therapeutics Revenue

Osiris Therapeutics's revenue was reported to be $142.82 m in FY, 2018
USD

Revenue (FY, 2018)

142.8m

Gross profit (FY, 2018)

104.7m

Gross profit margin (FY, 2018), %

73.3%

Net income (FY, 2018)

36.9m

Market capitalization (16-Apr-2019)

655.7m

Closing stock price (16-Apr-2019)

19.0

Cash (31-Dec-2018)

16.4m
Osiris Therapeutics's current market capitalization is $655.7 m.
Annual
USDFY, 2013FY, 2014FY, 2018

Revenue

142.8m

Cost of goods sold

38.1m

Gross profit

104.7m

Gross profit Margin, %

73%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Revenue

31.6m33.9m36.5m

Cost of goods sold

8.9m9.7m9.8m

Gross profit

22.8m24.2m26.7m

Gross profit Margin, %

72%71%73%
Annual
USDFY, 2013FY, 2014FY, 2017FY, 2018

Cash

2.4m2.2m3.1m16.4m

Accounts Receivable

15.3m10.0m26.1m22.5m

Inventories

1.9m9.8m11.3m9.6m

Current Assets

84.1m86.3m72.9m70.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Cash

1.8m2.3m2.7m946.0k1.6m15.8m3.4m23.1m31.7m

Accounts Receivable

6.8m26.5m23.5m20.6m

Inventories

1.7m2.3m5.5m8.8m13.3m15.8m11.0m11.1m10.6m

Current Assets

37.6m83.5m87.1m89.6m100.8m98.7m73.3m74.7m79.7m
Annual
USDFY, 2013FY, 2014FY, 2017FY, 2018

Net Income

8.8m36.9m

Depreciation and Amortization

587.0k940.0k688.0k873.0k

Inventories

(651.0k)(7.9m)

Accounts Payable

(2.8m)(57.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.3m)164.0k4.4m

Depreciation and Amortization

211.0k426.0k658.0k

Inventories

1.7m2.3m5.5m8.8m11.9m13.3m15.8m

Accounts Payable

4.0m8.0m9.3m9.8m9.2m9.6m
USDY, 2018

Revenue/Employee

420.7k

Financial Leverage

1.3 x
Show all financial metrics

Osiris Therapeutics Online and Social Media Presence

Embed Graph

Osiris Therapeutics News and Updates

Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris t…

OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc

NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") (NASDAQ:OSIR) with Smith & Nephew plc. Click here for more information:...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" or the "Company") (NASDAQ: OSIR) in connection with the proposed acquisition of the Company ...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR

NEW YORK, March 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM:...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.

NEW YORK, March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Smith & Nephew plc. Stockholders will...

Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.

LONDON, March 12, 2019 /PRNewswire/ -- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone...
Show more

Osiris Therapeutics Blogs

Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.

LONDON , March 12, 2019 /PRNewswire/ --  Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft a…

OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS

The post OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS appeared first on Osiris Therapeutics, Inc..

Charles A. Rienhart, III

Charles A. Rienhart, III Kathy.Symes@na… Tue, 09/11/2018 - 17:12 Charles A. Rienhart, III Board Member Charles A. Reinhart, III was appointed to the Board in September 2018. Mr. Reinhart is currently the Chief Financial Officer at Pacira. He joined Pacira …

Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial

The post Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial appeared first on…

Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018

The post Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 appeared first on Osiris Therapeutics, Inc..

Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers

The post Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers appeared first on Osiris Therapeutics, Inc..
Show more

Osiris Therapeutics Frequently Asked Questions

  • When was Osiris Therapeutics founded?

    Osiris Therapeutics was founded in 1992.

  • Who are Osiris Therapeutics key executives?

    Osiris Therapeutics's key executives are Linda Chang and Jason Keefer.

  • How many employees does Osiris Therapeutics have?

    Osiris Therapeutics has 342 employees.

  • What is Osiris Therapeutics revenue?

    Latest Osiris Therapeutics annual revenue is $142.8 m.

  • What is Osiris Therapeutics revenue per employee?

    Latest Osiris Therapeutics revenue per employee is $417.6 k.

  • Who are Osiris Therapeutics competitors?

    Competitors of Osiris Therapeutics include GenSight Biologics, Immusoft and Reneuron Group.

  • Where is Osiris Therapeutics headquarters?

    Osiris Therapeutics headquarters is located at 7015 Albert Einstein Dr, Columbia.

  • Where are Osiris Therapeutics offices?

    Osiris Therapeutics has an office in Columbia.

  • How many offices does Osiris Therapeutics have?

    Osiris Therapeutics has 1 office.